Last Price$222.71.6%
Market Cap$21.9B
LTM EBITDA margin
22.7%
5Y avg
22.8%
Medical - Devices industry
median
(28.5%)
Stock quality & Intrinsic value
6/10
(0.1%) overvalued
STERIS plc EBITDA margin
Annual
Quarterly
LTM
Industry median
Company stand-alone
Crunching data... Almost there!
| Mar'05 | Mar'06 | Mar'07 | Mar'08 | Mar'09 | Mar'10 | Mar'11 | Mar'12 | Mar'13 | Mar'14 | Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| EBITDA margin | 17.5% | 14.7% | 16.7% | 14.9% | 18.2% | 20.8% | 11.6% | 20.6% | 19.6% | 18.7% | 17.3% | 19.6% | 19.3% | 22.7% | 24.9% | 24.5% | 25.8% | 20.9% | 27.1% | 27.5% |
Overvalued or undervalued?
Check the intrinsic value for STE
and see if it's the right time to invest.
STERIS plc (STE) EBITDA margin comparison analysis
General
LTM EBITDA margin
OTHER METRICS
Company name
Revenue growth
EPS growth
Net Income margin
STERIS plcSTE
22.7%
3.6%
257.9%
7.4%
Median Peer Set
22.4%
5.6%
72.0%
12.7%
Zimmer Biomet Holdings, Inc.ZBH
32.0%
6.5%
253.2%
13.8%
Edwards Lifesciences CorporationEW
29.0%
(9.4%)
202.2%
76.7%
Abbott LaboratoriesABT
25.9%
4.6%
134.5%
31.9%
Boston Scientific CorporationBSX
23.1%
17.6%
16.7%
11.1%
DexCom, Inc.DXCM
22.7%
11.3%
(1.4%)
14.3%
Medtronic plcMDT
22.2%
3.6%
(2.1%)
11.4%
Insulet CorporationPODD
21.6%
30.0%
4,364.6%
12.2%
Stryker CorporationSYK
19.8%
10.2%
(5.8%)
13.2%
Align Technology, Inc.ALGN
18.7%
3.4%
26.0%
11.5%
Koninklijke Philips N.V.PHG
5.5%
(0.8%)
118.1%
(3.9%)
STE key stats
USD
Millions
Billions
Annual
Quarterly
Trailing
Key stats
Income statement
Balance sheet
Cash Flow Statement
Valuation
Ratios
Per share
Per employee
Dividends & Yields
| Mar'05 | Mar'06 | Mar'07 | Mar'08 | Mar'09 | Mar'10 | Mar'11 | Mar'12 | Mar'13 | Mar'14 | Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
% growth | 1,119.7 3.0% | 1,160.3 3.6% | 1,197.4 3.2% | 1,265.1 5.7% | 1,298.5 2.6% | 1,257.7 (3.1%) | 1,207.4 (4.0%) | 1,391.5 15.2% | 1,501.9 7.9% | 1,622.3 8.0% | 1,850.3 14.1% | 2,238.8 21.0% | 2,612.8 16.7% | 2,620.0 0.3% | 2,782.2 6.2% | 3,030.9 8.9% | 3,107.5 2.5% | 4,585.1 47.5% | 4,957.8 8.1% | 5,138.7 3.6% |
| Cost of Goods Sold (COGS) | 648.1 | 676.1 | 692.6 | 741.1 | 771.8 | 718.6 | 761.3 | 823.0 | 880.6 | 972.6 | 1,076.0 | 1,343.3 | 1,587.1 | 1,525.8 | 1,606.7 | 1,711.0 | 1,764.4 | 2,568.7 | 2,798.1 | 2,920.5 |
% margin | 471.7 42.1% | 484.2 41.7% | 504.8 42.2% | 524.0 41.4% | 526.7 40.6% | 539.2 42.9% | 446.2 37.0% | 568.5 40.9% | 621.3 41.4% | 649.6 40.0% | 774.3 41.8% | 895.5 40.0% | 1,025.6 39.3% | 1,094.2 41.8% | 1,175.4 42.2% | 1,319.9 43.5% | 1,343.1 43.2% | 2,016.4 44.0% | 2,159.7 43.6% | 2,218.2 43.2% |
| Operating Expenses | 326.7 | 349.2 | 360.5 | 385.0 | 347.7 | 330.6 | 359.7 | 345.5 | 395.8 | 429.6 | 547.5 | 683.4 | 739.5 | 690.7 | 733.0 | 782.3 | 797.6 | 1,590.7 | 1,400.5 | 1,382.0 |
| Research & Development Expenses (R&D) | 35.5 | 33.6 | 33.6 | 36.9 | 32.8 | 34.0 | 34.3 | 36.0 | 41.3 | 48.6 | 54.1 | 56.7 | 59.4 | 60.8 | 63.0 | 65.5 | 66.3 | 87.9 | 101.6 | 103.7 |
| Selling, General & Administrative Expenses (SG&A) | 291.1 | 315.6 | 326.9 | 348.0 | 315.0 | 296.6 | 325.5 | 309.6 | 354.5 | 381.0 | 493.3 | 626.7 | 680.1 | 629.9 | 669.9 | 716.7 | 731.3 | 1,502.8 | 1,298.9 | 1,252.3 |
% margin | 145.0 12.9% | 109.7 9.5% | 137.7 11.5% | 123.5 9.8% | 175.4 13.5% | 203.7 16.2% | 85.2 7.1% | 222.3 16.0% | 242.8 16.2% | 206.8 12.7% | 227.2 12.3% | 212.9 9.5% | 227.6 8.7% | 403.5 15.4% | 411.5 14.8% | 341.1 11.3% | 323.3 10.4% | 425.6 9.3% | 268.2 5.4% | 836.1 16.3% |
| Interest Income | 0.0 | 0.0 | 0.0 | 0.0 | 1.6 | 1.3 | 0.6 | 0.9 | 0.0 | 0.3 | 0.8 | 1.7 | 1.6 | 2.2 | 3.0 | 2.0 | 6.3 | 6.3 | 108.0 | 11.0 |
| Interest Expense | 3.1 | 44.9 | 16.9 | 34.7 | 10.6 | 13.2 | 12.0 | 12.1 | 15.7 | 18.8 | 19.2 | 42.7 | 44.5 | 50.6 | 45.0 | 40.3 | 37.2 | 89.6 | 109.6 | 144.4 |
| Pre-tax Income | 141.9 | 108.1 | 132.9 | 119.8 | 166.5 | 191.8 | 73.8 | 211.1 | 227.1 | 188.4 | 208.8 | 171.9 | 184.6 | 355.0 | 369.5 | 498.7 | 517.5 | 314.5 | 157.3 | 702.8 |
% effective tax rate | 56.0 39.4% | 45.2 41.8% | 51.8 39.0% | 42.7 35.6% | 55.8 33.5% | 63.3 33.0% | 22.6 30.6% | 75.0 35.5% | 67.1 29.6% | 58.9 31.3% | 73.8 35.3% | 60.3 35.1% | 74.0 40.1% | 63.4 17.8% | 64.4 17.4% | 90.9 18.2% | 120.7 23.3% | 71.6 22.8% | 51.5 32.8% | 149.5 21.3% |
% margin | 86.0 7.7% | 70.3 6.1% | 82.2 6.9% | 77.1 6.1% | 110.7 8.5% | 128.5 10.2% | 51.3 4.2% | 136.1 9.8% | 160.0 10.7% | 129.4 8.0% | 135.1 7.3% | 110.8 4.9% | 110.0 4.2% | 290.9 11.1% | 304.1 10.9% | 407.7 13.5% | 397.4 12.8% | 243.9 5.3% | 107.0 2.2% | 378.2 7.4% |
| EPS | 1.24 | 1.03 | 1.26 | 1.22 | 1.88 | 2.18 | 0.86 | 2.33 | 2.74 | 2.20 | 2.27 | 1.57 | 1.29 | 3.42 | 3.59 | 4.81 | 4.66 | 2.50 | 1.07 | 3.83 |
| Diluted EPS | 1.23 | 1.02 | 1.25 | 1.20 | 1.86 | 2.16 | 0.85 | 2.31 | 2.72 | 2.17 | 2.25 | 1.56 | 1.28 | 3.39 | 3.56 | 4.76 | 4.63 | 2.48 | 1.07 | 3.81 |
% margin | 196.2 17.5% | 171.0 14.7% | 200.4 16.7% | 188.6 14.9% | 235.8 18.2% | 261.2 20.8% | 140.4 11.6% | 286.1 20.6% | 294.5 19.6% | 303.8 18.7% | 319.5 17.3% | 438.7 19.6% | 503.0 19.3% | 594.5 22.7% | 693.1 24.9% | 743.2 24.5% | 800.3 25.8% | 957.2 20.9% | 1,344.0 27.1% | 1,412.4 27.5% |
Discover more Stock Ideas
Undervalued stocks right now
Discover the top 20 best undervalued stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.
3M Return 32.1%
S&P Outperformance 19.1%
Next 3M Predicted Return 20.3%
Undervalued growth stocks
Discover the top 20 best undervalued large-cap growth stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.
3M Return 35.3%
S&P Outperformance 22.3%
Next 3M Predicted Return 26.8%
Undervalued dividend stocks
Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Mar 2025.
3M Return 28.4%
S&P Outperformance 15.4%
Next 3M Predicted Return 16.9%
FAQ
1) What is STERIS plc's EBITDA margin?
As of today, Microsoft Corp's last 12-month EBITDA margin is 22.7%, based on the financial report for Dec 31, 2024 (Q4’2024). The average annual EBITDA margin for STERIS plc have been 21.8% over the past three years, and 23.9% over the past five years.
2) Is STERIS plc's EBITDA margin Good?
As of today, STERIS plc's EBITDA margin is 22.7%, which is higher than industry median of (28.5%). It indicates that STERIS plc's EBITDA margin is Good.